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Background: A growing literature indicates that genetic variation, in combi-
nation with adverse early life experiences, shapes risk for later mental illness.
Recent work also suggests that molecular variation at the ADCYAP1R1 locus is
associated with posttraumatic stress disorder (PTSD) in women. We sought to
test whether childhood maltreatment (CM) interacts with ADCYAP1R1 geno-
type to predict PTSD in women. Methods: Data were obtained from 495 adult
female participants from the Detroit Neighborhood Health Study. Genotyping of
rs2267735, an ADCYAP1R1 variant, was conducted via TaqMan assay. PTSD,
depression, and CM exposure were assessed via structured interviews. Main and
interacting effects of ADCYAP1R1 and CM levels on past month PTSD and post-
traumatic stress (PTS) severity were examined using logistic regression and a
general linear model, respectively. As a secondary analysis, we also assessed main
and interacting effects of ADCYAP1R1 and CM variation on risk of past-month
depression diagnosis and symptom severity. Results: No significant main effects
were observed for ADCYAP1R1 genotype on either PTSD/PTS severity. In con-
trast, a significant ADCYAP1R1 × CM interaction was observed for both past
month PTSD and PTS severity, with carriers of the “C” allele showing enhanced
risk for these outcomes among women exposed to CM. No significant main or
interaction effects were observed for past month depression/depression severity.
Conclusions: Genetic variation at the ADCYAP1R1 locus interacts with CM
to shape risk of later PTSD, but not depression, among women. The molecu-
lar mechanisms contributing to this interaction require further investigation.
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INTRODUCTION
Posttraumatic stress disorder (PTSD) is an anx-
iety disorder that emerges following exposure to
trauma. Although a substantial proportion (50–90%;
[1, 2]) of Americans are exposed to traumatic events
in their lifetime, only a minority (8–20%) go on
to develop PTSD.[1] Trauma exposure character-
istics such as type or severity do not fully explain
differences in risk of PTSD, suggesting that addi-
tional factors, both genetic and environmental,[3]
contribute to risk of PTSD following trauma
exposure.
One of the most potent predictors of PTSD is
childhood maltreatment (CM). For example, meta-
analyses indicate that CM exposure is one of the
most robust risk factors for PTSD among trauma-
exposed adults.[4, 5] Similarly, prospective studies of
PTSD risk show that among adults with documented
cases of childhood abuse, the odds of current and
lifetime PTSD are 1.86 and 1.75 greater, respec-
tively, compared to non-CM-exposed controls.[6] No-
tably, across all types of prospectively assessed abuse,
women are more than twice as likely as men to develop
PTSD.[7]
Recently, Ressler et al.[8] reported that rs2267735,
a variant in the pituitary adenylate cyclase activating
polypeptide 1 receptor type I gene (ADCYAP1R1)
predicted PTSD, but not depression, diagnosis, and
symptoms in women only. ADCYAP1R1 serves as a
receptor to pituitary adenylate cyclase-activating
polypeptide (PACAP), a neuropeptide critical to the
regulation of prolonged stress circuit activation in
both the central and peripheral nervous systems.[9]
Although the functional significance of the rs2267735
ADCYAP1R1 variant is not currently known, its loca-
tion within a predicted estrogen response element,[8]
combined with evidence indicating that estrogen influ-
ences ADCYAP1R1 gene expression,[8, 10] suggests the
plausibility of potential sex-specific effects of rs2267735.
Nevertheless, recently, Chang et al.[11] failed to replicate
the initial report of an rs2267735-PTSD association
in two independent samples, although the direction
of the reported effects for females was in the expected
direction.
In light of these recent findings, and the exten-
sive literature confirming the potent effect of CM
on risk of mental illness during adulthood (reviewed
in [12, 13]), we genotyped rs2267735 specifically in fe-
males to explore possible main and interacting ef-
fects of ADCYAP1R1 and CM variation on risk of
PTSD. In addition, due to the substantial genetic
overlap between PTSD and depression,[14] and the
possibility of previously undetected gene–environment
interactions for depression at this locus,[8] we also as-
sessed main and interacting effects of ADCYAP1R1 and




Samples for this study were drawn from the Detroit Neighborhood
Health Study (DNHS) The DNHS is a population-representative
cohort study of adult residents residing in Detroit and has been
described.[15,16] In brief, 1,547 adult participants (age 18 years or older)
were selected from the Detroit population to participate in wave 1 of
the DNHS via a telephone survey by choosing a probability sample of
households within the city limits of Detroit and then randomly select-
ing one adult from each household. A dual-frame probability sample
design was employed to draw a sample of residential addresses, obtain-
ing telephone numbers from two sources: (1) US Postal Service De-
livery Sequence File (DSF), which consists of the entire Detroit popu-
lation and includes nontelephone and cellular phone-only households
and (2) a list-assisted sampling random-digit-dial frame, covering De-
troit households that are not residential directory-listed numbers (the
unlisted number frame). Telephone numbers in these two databases
were matched to identify the sample addresses that have at least one
listed landline telephone number; these people were then contacted by
telephone to participate in the telephone survey. A postal mail effort
was also initiated in order to invite the other part of the sample with
no listed landline, telephone, or cell phone to participate in the sur-
vey. The overall response rate among those eligible was 53.0%, which
compares very favorably with other true population-based samples that
have collected both interview and biologic data.[17] The DNHS was
approved by the Institutional Review Board at the University of Michi-
gan. All participants provided informed consent prior to participating
in this study.
DNA SAMPLES AND GENOTYPING
Previously extracted DNA samples from 514 available female par-
ticipants in waves 1 and 2 were selected for inclusion in this study.
DNA samples were isolated from either whole blood or saliva in the
Wildman laboratory. Whole blood samples were isolated using Qi-
aAmp Mini kits (Qiagen, Valencia, CA) or the QuickGene DNA whole
blood kit (Fujifilm Life Sciences, Tokyo, Japan) following the manu-
facturers’ recommended protocol.Saliva samples were isolated using
Oragene OG-500 (DNAgenotek, Kanata, Canada) kit and following
the manufacturer’s recommended protocol.
Genotyping of rs2267735, located in an intronic region of the
ACYAP1R1 locus, was genotyped in the Ressler laboratory using a
TaqMan R© assay (Life Technologies Corporation, Carlsbad, CA) as
previously described.[8] Genotyping was conducted by individuals who
were blinded to participants’ PTSD and depression status.
ASSESSMENT OF PTSD AND DEPRESSION
Structured telephone interviews assessed participants’ PTSD and
depression symptoms as previously described.[15,18] Symptoms were
assessed as occurring within the past month in order to approximate the
time frame used in the Ressler et al study.[8] Briefly, PTSD diagnosis
was assessed via telephone using a structured diagnostic interview val-
idated against the Clinician-Administered PTSD Scale for DSM-IV
(CAPS). Participants were initially asked to identify potentially trau-
matic events (PTEs) that they experienced in the past from a list of
19 events.[19] PTSD symptoms were then assessed by referencing two
traumatic events that the respondent may have experienced: one that
the participant regarded as the worst and one randomly selected event
from the remaining PTEs a respondent may have experienced. Re-
spondents were considered affected by past month PTSD if all six
DSM-IV criteria were met in reference to either the worst or the ran-
dom event and they reported being affected by the symptoms within
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the past month. PTS severity was assessed by summing participants’
ratings of the 17 posttraumatic symptoms on a scale indicating the
degree to which the respondent had been bothered by a particular
symptom as a result of the worst trauma, ranging from 1 (not at all)
to 5 (extremely); total PTS scores could thus range from 17 to 85.
Past month PTS severity equated to the total PTS score if partici-
pants reported being affected by the symptoms within the past month;
otherwise, past month PTS severity was set to 0.
Depressive symptoms were evaluated with a structured interview
based on a modified version of Patient Health Questionnaire (PHQ-
9).[20] Each of the nine questions was scored as 0 (not at all) to 3
(nearly every day), such that scores ranged from 0 to 27.[20] Past
month depression cases were participants who reported depressed
mood or anhedonia and at least one additional symptom for “more
than half the days” for two or more weeks, whose symptoms were
present during the past month and occurred together. One symptom,
“thoughts that you would be better off dead or of hurting yourself
in some way,” counted if present at all, regardless of duration. Past
month depression severity was the sum of symptoms reported as be-
ing present within the past month, such that scores could range from
0 to 27.
PTSD and depression diagnoses obtained from the telephone in-
terview responses has been validated in a random subsample of partic-
ipants via in-person clinical interview using the CAPS and Structured
Clinical Interview for DSM-IV Disorders, which has been described
previously.[15,21] The comparison showed high internal consistency
and concordance.
ASSESSMENT OF CM
Exposure to CM was assessed in the wave 2 survey and was scored on
a continuous scale following the method employed in.[22] Briefly, CM
questions were drawn from the Conflict Tactics Scale (CTS),[23] the
Childhood Trauma Scale (CTQ),[24] and Wyatt’s eight-item interview
guide [25] as implemented by the Nurse’s Health Study II.[26] CTQ
items assessed physical abuse (e.g. “People in my family hit me so
hard that it left me with bruises and marks”), and emotional abuse
(e.g. “People in my family said hurtful or insulting things to me”)
assessed before age 11. Response options were rated on a 5-point scale
and ranged from “never true” (1) to “very often true” (5). CTS items
assessed physical abuse before age 18 (e.g. “Did your parent, step-
parent, or adult guardian ever push, grab, or shove you”) with response
options ranging from “never” to “more than a few times.” Sexual abuse
before age 18 was assessed with two items regarding sexual assault and
rape used in the Nurse’s Health Study II (NHSII)[26] (e.g. “Were
you ever touched in a sexual way by an adult or older child”) which
was coded as occurring once, multiple times, or never. CTQ physical
abuse and emotional abuse questions, CTS physical questions, and
NHSII-modified Wyatt’s sexual abuse questions were recoded into
three-level variables indicating whether each abuse type occurred: (1)
never, (2) rarely or sometimes, or (3) often. Scores were summed to
create a continuous variable ranging from 0 to 22.In addition, number
of CM types (i.e. the presence of exposure to physical, emotional, and
sexual abuse) was assessed in order to provide a visual representation
of the association among CM, rs2267735 genotype, and past month
PTSD.
STATISTICAL ANALYSIS
The distribution of the primary study variables (past month PTSD,
past month depression, CM) was calculated using means with stan-
dard deviations for continuous variables, and frequencies and per-
cents for categorical variables. Bivariate associations were assessed for
each variable with respect to rs2267735 genotype. Chi-square tests
were performed for categorical variable comparisons; for continu-
ous variable comparisons, Kruskal–Wallis tests were used. Hardy–
Weinberg equilibrium of rs2267735 genotypes was assessed chi-
square tests as applied in the online Hardy–Weinberg Equilibrium
calculator.[27]
Past month PTSD and past month depression were modeled us-
ing logistic regression. To assess possible subthreshold effects of
ADCYAP1R1 variation on these mental illnesses, past month PTS
severity and past month depression severity were modeled using a gen-
eral linear model (GLM), with the severity measure log transformed
to improve normality. We assessed main effects of each outcome us-
ing the continuous (0–22) CM measure and rs2267735 genotype as the
main predictors, controlling for race and age as covariates. In addition,
in order to isolate the effects of these main predictors (and their inter-
action) on each disorder, net of the effects of the other disorder, we
controlled for comorbid past month depression/depression severity (in
PTSD/PTS severity models) and comorbid past month PTSD/PTS
severity (in depression/depression severity models). Following main
effect analyses, we assessed the presence/absence of CM × rs2267735
genotype interactions by including an interaction term in each of the
main effects models. Effect estimates for were accepted as significant
if P < .05. An additive effect of rs2267735 genotype was assumed in all
models, with GG designated as the reference genotype.
To further confirm our results obtained by logistic regres-
sion analyses, which included a relatively small number of past
month PTSD and depression cases, we performed permutation
tests. We used the logregperm package[28] in R v2.13.0 to
carry out 100,000 permutations to test the primary study vari-
ables (i.e. single nucleotide polymorphism or SNP, CM, and
SNP × CM in interaction models) with its residuals from a
linear regression on the other independent variables (age, race,
etc).The residuals were subjected to random permutation, binary
logistic regression was reperformed, and the permutation P-value
(i.e. the fraction of the permutations that have a likelihood-based
P-value less than or equal to that for the unpermuted data) was
calculated.
To further confirm that our results obtained by linear regression
did not depend on normal distributional assumptions, we used the
ape package[29] in R v2.13.0 to conduct 100,000 permutation tests.
We performed linear regression (least squares) to obtain a t-value as
a reference t-value (tref) for key independent variables (SNP, CA, and
SNP × CA), randomly permuted our dependent variables, and then
reconducted linear regression to obtain t-values for the same key in-
dependent variables. The permutation P-value was then computed as
the proportion of t-values greater than or equal to the reference t-
value(tref).
To assess possible genotype-dependent correlations between past
month PTS or depression severity and CM exposure, partial corre-
lations, controlling for age, were assessed between: (i) past month
PTS severity and CM and (ii) past month depression severity and
CM. Partial correlations were determined using the Spearman rank
method due to nonnormality of the data. Z-scores were employed to
test for the presence of significant differences in correlations between
genotypes.
Analyses of past month PTSD/PTS severity and past month depres-
sion/depression severity were restricted to participants with available
CM data; for PTSD/PTS severity, analyses were further restricted
to trauma-exposed participants. In addition, due to the race-specific
genotype × environment interactions that have been reported in the
child abuse literature,[30,31] main effect and interaction analyses were
restricted to participants who self-identified as either white or African-
American, that is, those self-reported race categories that had suffi-
cient members to be included in analyses. In addition, logistic regres-
sion and GLM analyses were run using African-American participants
only.
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TABLE 1. Distribution of past month PTSD, depression, CM, and ADCYAP1R1 genotype (n = 401 for PTSD, n = 430
for others)
PTSD Depression CM exposure Number of CM types
Genotype No Yes No Yes 0–22 0 1 2+
GG 51 2 54 6 4.68 ± 4.03 37 7 16
CG 192 10 195 21 4.98 ± 4.45 117 54 45
CC 135 11 134 20 5.55 ± 5.52 80 34 40
Total 378 23 383 47 5.14 ± 4.81 234 95 101
Chi-square 1.481a 1.046 0.198b 0.969





Genotypes at the rs2267735 locus were successfully
determined for 495 of 514 participants (success rate
96.3%). ADCYAP1R1 genotypes at the rs2267735 were
in Hardy–Weinberg Equilibrium in the full sample
(P = .31). The frequency of the common “C” allele was
60.2%.
Among all genotyped participants, 11.7% were white,
83.1% were African American, and 5.2% reported be-
longing to another race/ethnic group. Table 1 shows
the distribution of the main study variables of inter-
est by ADCYAP1R1 genotype in our analytic sam-
ple. Among trauma-exposed participants, 23 (6%) re-
ported symptoms consistent with past month PTSD.
A larger proportion (11%) of participants reported
symptoms of past month depression. Past month
PTSD, past month depression, and average CM scores
(Mean = 5.14, SD = 4.81) did not vary by ADCYAP1R1
genotype.
Table 2 shows the results of main and interaction lo-
gistic regression analyses of the effect of ADCAYP1R1
genotype and CM on PTSD, controlling for age, race,
and past month depression. In main effect analyses,
the odds of past month PTSD were significantly as-
sociated with exposure to CM (P < .002, permutation
P = .0021): for every one-unit increase in CM score,
there was a 15% increase in odds of past month PTSD. In
contrast, there was no significant association between
ADCYAP1R1 genotype and past month PTSD (P = .60).
However, results from interaction effect analyses showed
that participants with one versus no “C” alleles at the
ADCAYP1R1 rs2267735 locus showed a 17% increased
odds of past month PTSD for every one-unit increase
in CM score (P = .029, permutation P = .030). Analy-
ses based on African-American participants only showed
similar results (Table S1).
Results from our secondary analyses assessing the joint
and interacting effects of ADCAYP1R1 genotype and
CM exposure on depression are presented in Table 3.
Similar to the PTSD results, the odds of past month de-
pression were significantly associated with exposure to
CM (OR = 1.12, 95% CI = 1.05, 1.20, P = .001, per-
mutation P = .0013), but not ADCYAP1R1 genotype,
in main effect analyses (Table 3A). In contrast, no sig-
nificant interaction was observed between ADCYAP1R1
genotype and CM (P = .226; Table 3B). Analyses based
on African-American participants only showed similar
results (Table S2). Results were similar when PTS sever-
ity (Table 4) and depression severity (data not shown)
were used as outcomes.
Correlations between CM and past month PTS and
past month depression severity stratified by genotype
are reported in Table 5. Significant partial correlations,
TABLE 2. Main (A) and interaction (B) effect logistic regression model results predicting past month PTSD (n = 380)
A. Main effect B. Interaction effect
Adjusted OR 95% CI P Adjusted OR 95% CI P
Age 0.97 0.93 1.00 .045 0.96 0.93 1.00 .034
African-American 0.17 0.05 0.57 .004 0.15 0.04 0.51 .003
Past month depression 6.42 2.26 18.19 <.001 5.62 1.90 16.63 .002
CM 1.15 1.06 1.26 <.002 0.79 0.56 1.12 .192
ADCYAP1R1 “C” allele 1.23 0.57 2.64 .596 0.38 0.11 1.33 .130
ADCYAP1R1 × CM — — — — 1.17 1.02 1.34 .029
–2LogL 127.87 123.05
CM, childhood maltreatment measured on a scale of 0–22.
Comparing the main effect and interaction models, Chi-square = 4.82 P = .028.
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TABLE 3. Main (A) and interaction (B) effect logistic regression model results predicting past month depression
(n = 409)
A. Main effect B. Interaction effect
Adjusted OR 95% CI P Adjusted OR 95% CI P
Age 0.99 0.97 1.01 .356 0.99 0.97 1.01 .345
African-American 1.33 0.44 4.01 .619 1.25 0.41 3.80 .693
Past month PTSD 5.41 1.96 14.96 .001 4.67 1.63 13.37 .004
CM 1.12 1.05 1.20 <.001 0.98 0.77 1.23 .836
ADCYAP1R1 “C” allele 0.90 0.54 1.49 .681 0.61 0.27 1.36 .223
ADCYAP1R1 × CM — — — — 1.06 0.96 1.17 .226
–2LogL 242.68 241.21
CM, childhood maltreatment measured on a scale of 0–22.
Comparing the main effect and interaction models, Chi-square = 1.47 P = .225.
controlling for age, were observed between CM score
and PTS severity in the full analytic sample (r = .290,
P < .001); however, stratification by ADCYAP1R1 geno-
type showed that these correlations were significant only
among genotypes containing the “C” allele. Moreover,
correlation coefficients were significantly higher in the
CC versus GG group (z-value for difference, 2.071,
P < .05) and in the CC versus CG group (z-value
for difference, 2.868, P < .01). In contrast, CM score
and past month depression severity were significantly
correlated in both the full analytic sample (r = .306,
P < .001, n = 429) and in the three subsamples de-
fined by ADCYAP1R1 genotype, and none of the three
correlation coefficients differed significantly from one
another.
Figure 1 provides a visual summary of the
ADCYAP1R1 × CM interactions detected in the PTSD-
related analyses. Among participants exposed to two
or more CM types, those with two “C” alleles show
a markedly increased prevalence of past month PTSD
TABLE 4. Adjusted main (A) and interaction (B) effect linear regression model results predicting past month PTS
severity (n = 380)
A. Main effect B. Interaction effect
b 95% CI P b 95% CI P
Age − 0.002 − 0.004 0.000 .582 − 0.001 − 0.003 0.000 .677
African-American − 0.188 − 0.375 − 0.001 .200 − 0.185 − 0.370 0.000 .205
Depression severity 0.645 0.000 1.289 <.0001 0.649 0.000 1.297 <.0001
CM 0.047 0.000 0.093 <.0001 − 0.031 − 0.062 0.000 .425
ADCYAP1R1 “C” allele − 0.018 − 0.036 0.000 .805 − 0.188 − 0.377 0.000 .083
ADCYAP1R1 × CM — — — — 0.033 0.000 0.066 .037
Adj R2 .175 .182
CM, childhood maltreatment measured on a scale of 0–22.
TABLE 5. Correlationa between childhood maltreatment and past month PTSD (A) and depression (B)
Genotype GG CG CC
A. Correlation between childhood maltreatment and past month PTS severity (n = 401)
Number of participants 53 202 146
Spearman correlation R-value .162 .187 .465
P-value .251 .008 <.0001
Z-value for difference (Z) GG/CG = 0.163 CG/CC = 2.868** CC/GG = 2.071*
B. Correlation between childhood maltreatment and past month depression symptom severity (n = 429)
Number of participants 60 215 154
Spearman correlation R-value .315 .289 .346
P-value .015 <.001 .001
Z-value for difference (Z) GG/CG = 0.192 CG/CC = 0.596 CC/GG = 0.224
aPartial correlation controlling for age.
*Significant at P < 0.05; **significant at P < 0.01.
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Figure 1. The effect of ADCYAP1R1 genetic variation on risk of PTSD in women is moderated by exposure to CM. Shown is the percent
of DNHS participants (n = 401; all female) with past month PTSD by ADCYAP1R1 rs2267735 genotype (CC versus CG/GG genotypes)
and number of CM types (physical, sexual, and emotional abuse).
compared to those with one or no “C” alleles. In con-
trast, among participants unexposed to CM, those with
two “C” alleles show a slightly reduced prevalence of
past month PTSD compared to those with one or no
“C” alleles.
DISCUSSION
In this study, we sought to examine the joint and inter-
acting effects of CM and ADCYAP1R1 genetic variation
on risk of PTSD in women. We also tested for evidence
of these effects on depression as a secondary analysis.
Results showed that CM had a significant main effect
on both PTSD and depression, and that the magnitude
of the CM effect size was similar in both cases. In addi-
tion, we observed a significant ADCYAP1R1 × CM in-
teraction in predicting PTSD, whereby women exposed
to CM carrying one or more ADCYAP1R1 “C” alleles
showed an increased risk of PTSD and PTS severity.
These results were further corroborated by our detec-
tion of a significant PTS severity/CM correlation among
C allele carriers only, with correlation coefficients that
differed significantly between the “riskiest” CC genotype
compared to G-carrying genotypes. This suggests CM
is associated with increased risk of PTSD most strongly
among persons with the “CC” genotype. Notably, signif-
icant interactions and differing correlations by genotype
were not detected in our secondary analyses of depres-
sion, suggesting that PTSD is the primary phenotype
influenced by genetic variation, in conjunction with CM
exposure, at the ADCYAP1R1 locus.
Our finding of a significant PTSD-related
ADCYAP1R1 × CM interaction lends support to
recent work reported by Ressler et al.,[8] which found a
significant association between ADCYAP1R1 variation
and risk of PTSD, but not depression and other mental
illnesses. In the present report, the PTSD-specific
association of ADCYAP1R1 variation was revealed only
in interaction analysis with CM, rather than in main
effect analyses as in the original work reported by
Ressler et al.
However, the Grady Trauma project cohort, on which
the Ressler et al study was based, is a low-income study
population recruited from an urban hospital setting in
which prior trauma levels, possibly including CM, may
be higher than those in the DNHS. Thus, ADCYAP1R1
genetic effects observed in the Grady cohort may only
be apparent in the DNHS when the latter is stratified
according to degree of previous (i.e. CM) trauma ex-
posure. Indeed, when the present DNHS study sample
is limited to those in the upper quartile of CM expo-
sure, we find that, controlling for similar covariates to
the Ressler et al. study (i.e. age and number of pre-
vious trauma types), there is a significant (P = 0.04)
main effect of ADCYAP1R1 variation for PTSD; this
effect is not observed for depression (P = 0.1629). Al-
though it has been argued that environmental risk fac-
tors should be included in genetic studies only once ro-
bust genetic associations have been identified,[32] find-
ings from this study emphasize importance of assessing
contextual factors that may influence the effect of ge-
netic variation on outcomes of interest,[33] in this case
PTSD.
PACAP and its receptor ADCYAP1R1 have a range of
known functions with implications for mental health and
illness, including regulation of the stress response,[9, 34]
mediation of adult neurogenesis in the lateral ventri-
cle and hippocampus,[35] and transcriptional control of
neurotrophic factors important to normal neural devel-
opment (i.e. BDNF).[36] In addition to its recent as-
sociation with PTSD, genetic variation in and around
ADCYAP1R1 has also been previously implicated in
other mental illnesses, including schizophrenia[37] and
major depression,[38] although these associations have
been at SNPs other than the one tested in this report.
Notably, PACAP genetic variation was significantly
associated with bilateral hippocampal volume in
schizophrenics, but not controls, identifying an
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intermediate phenotype for schizophrenia that is con-
sistent with known PACAP-ADCAYP1R1 function.[37]
Moreover, the SNP associated with MDD, which oc-
curs ∼4,200 bp downstream of ADCYAP1R1, also
showed a significant male-specific association with the
disorder.[38] The SNP examined here, r2267735, is
particularly interesting in its apparent increased as-
sociation with female risk, in that the SNP lies
within a putative estrogen response element and
was shown to associate with symptoms in a female-
specific manner.[8] Thus, it remains possible that ad-
ditional SNPs within ADCYAP1R1 may show main
or interacting effects with other mental illnesses,
with some of these occurring in a sex-specific
manner.
Our results should be evaluated in light of existing
study limitations. First, CM was assessed via retrospec-
tive self-report during adulthood, which could have in-
troduced recall bias into our CM measure. However,
previous work has shown that retrospective self-report
during adulthood among those with documented CM
cases is associated with underreporting of physical[39]
and sexual[40] abuse, suggesting that our estimates of
CM are likely to be underestimates. Second, given the
relatively small number of participants who reported
belonging to non-African-American race/ethnic back-
grounds, we were unable to assess the possible exis-
tence of race-specific ADCYAP1R1 × CM interactions,
as have recently been reported in other studies that in-
clude G × CM analyses.[30, 31] Future work in other co-
horts with both genetic and CM measures should eval-
uate this possibility. Third, although we used largely
the same dataset to test for the joint and interacting ef-
fects of ADCYAP1R1 and CM on two outcomes—PTSD
and depression—we did not correct our results for
multiple hypothesis testing. However, our primary anal-
yses focused on PTSD, with results that approached sig-
nificance following multiple correction for testing two
phenotypes (Table 2B; P = .029). Fourth, our CM mea-
sure included some traumas that were assessed for their
occurrence prior to both ages 11 and age 18 (e.g. phys-
ical abuse via the CTQ and CTS questions), whereas
others were assessed only prior to age 18 (e.g. sexual
abuse via the NHSII questions). Thus, we were unable
to determine whether there were specific developmental
periods of CM exposure that may have been contribut-
ing to the observed interactions. Finally, our study was
not able to directly assess whether participants’ PTSD
diagnosis and symptoms were due to a specific child-
hood abuse trauma. Thus, we cannot say with certainty
that the conditional risk of PTSD is significantly higher
among C allele carriers whose PTSD is attributable to a
specific CM event; our conclusions must necessarily be
limited to the observation that C allele carrying women
previously exposed to CM are at increased risk of PTSD
during adulthood.
Despite these limitations, our results provide novel
evidence that the impact of CM on PTSD is moderated
by genetic variation at ADCYAP1R1, a locus involved
in regulating the response to stress.[34] Future investiga-
tions focused on identifying the molecular mechanisms
contributing this moderation are warranted.
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